# Macomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/macomics

- Industry: Biotechnology
- Headquarters: Edinburgh, UK
- Website: www.macomics.com
- Total disclosed funding: $9.8M
- Latest round: Seed (Jul 21, 2021)
- Investors on record: 4

## About

Macomics Ltd is a biopharmaceutical company focused on developing innovative therapies targeting macrophage activity, utilizing their proprietary ENIGMAC™ platform to create genetic models for disease treatment.Founded in 2018, Macomics Ltd is headquartered in Edinburgh, UK. The company specializes in macrophage-targeted therapeutics and has undergone developments in its business focus since inception. The firm has completed 2 deals, with the most recent deal dated July 21, 2021, during which they raised GBP 4.24 million in a SEED funding round led by Epidarex Capital, along with participation from Caribou Property Limited and Scottish Enterprise. The current CEO is Steve M, and the founder, Luca Cassetta, has a background in biotechnology enterprises.Macomics specializes in developing innovative therapeutics that target macrophage activity through their proprietary ENIGMAC™ platform. This allows the creation of genetic models for various diseases, facilitating the discovery of new therapeutic targets that modulate macrophage functions. Their products address a variety of diseases, particularly where existing treatments are limited, including certain tumor subtypes, neurological disorders, and fibrotic and inflammatory diseases. Macomics primarily serves the European and North American markets, working with biopharmaceutical firms, research institutions, and clinical organizations engaged in drug discovery and development.Macomics generates revenue through partnerships and collaborations with biotechnology and pharmaceutical firms focusing on macrophage-targeted therapies. These business transactions typically involve contractual agreements for research and development services, offering proprietary insights, technologies, and therapeutic candidates. Collaborations may include milestone payments based on successful development stages and potential royalties from market-approved products. Their primary product targets macrophage activity for therapeutic benefits and is integrated into a pipeline for novel treatments, with pricing and financial arrangements tailored to individual clients.In July 2021, Macomics Ltd secured GBP 4.24 million in Seed funding, aimed at accelerating growth and expanding its scientific team. The company plans to launch new products that enhance their macrophage-targeting capabilities and is poised to explore expansion into additional markets in Europe and North America by the end of 2023. This funding will significantly support their initiatives in product development and team scaling.

## Funding rounds

- Seed, Jul 21, 2021, $5.8M — Epidarex Capital, Scottish Enterprise, Caribou Property Limited
- Seed, Jul 15, 2020, $4M — Epidarex Capital, Scottish Investment Bank

## Investors

- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Seed
- Scottish Investment Bank — Seed
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Seed
- Caribou Property Limited — Seed